Gastrografin (Gastrografin)
Other Medications · Approved since 1963
Description
Gastrografin is an iodinated contrast agent containing diatrizoate meglumine and diatrizoate sodium, classified as an ionic, high-osmolar contrast medium. In colorectal cancer care, it serves as a bowel preparation agent to enhance visualization during colon capsule endoscopy procedures. This radiopaque solution helps clear bowel contents and provides contrast enhancement for improved imaging quality during diagnostic procedures used in CRC screening and surveillance.
Mechanism of Action
Gastrografin works through its high osmolarity (approximately 1900 mOsm/kg), which draws fluid into the bowel lumen through osmotic effects, promoting bowel evacuation and cleansing. The iodinated compounds provide radiopaque contrast properties that enhance visualization of bowel structures and improve image quality during capsule endoscopy procedures.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Gastrografin |
| Category | Other Medications |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Hospital use other indication |
| Administration | Oral |
| Year Approved | 1963 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.